Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc. (AGNPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
agnpf · pe ratio · data through Aug 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Algernon Pharmaceuticals Inc. (AGNPF) measures how much investors pay for each dollar of the company's trailing earnings. AGNPF's current PE ratio of N/A is calculated by dividing its stock price of $0.44 by its TTM earnings per share of -$0.56.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-08-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Algernon Pharmaceuticals Inc.You AGNPF | $2M | N/A | — | -$0.56 |
 America Great Health AAGH | $4M | N/A | — | -$0.00 |
 Ayala Pharmaceuticals, Inc. ADXS | $26M | N/A | — | -$7.99 |
 Appili Therapeutics Inc. APLIF | $2M | N/A | — | -$0.02 |
 Health Sciences Group, Inc. HESG | $2M | N/A | — | -$0.03 |
 Universal Ibogaine Inc. IBOGF | $10M | N/A | — | -$0.06 |
 Imagion Biosystems Limited IBXXF | $7M | N/A | — | -$0.02 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-08-31Latest FY2025 | — | $-0.58 | — | |
2024-08-31 FY2024 | — | $-0.25 | — | |
2023-08-31 FY2023 | — | $-4.48 | — | |
2022-08-31 FY2022 | — | $-8.71 | — | |
2021-08-31 FY2021 | — | $-10.40 | — | |
2020-08-31 FY2020 | — | $-20.30 | — | |
2019-08-31 FY2019 | — | $-10.62 | — | |
2018-08-31 FY2018 | — | $-8.33 | — | |
2017-08-31 FY2017 | — | $-18.43 | — | |
2016-08-31 FY2016 | — | $-97.55 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Algernon Pharmaceuticals Inc. (AGNPF) measures how much investors pay for each dollar of the company's trailing earnings. AGNPF's current PE ratio of N/A is calculated by dividing its stock price of $0.44 by its TTM earnings per share of -$0.56.
Frequently asked questions
AGNPF pe ratio · 6 questionsAGNPF's current PE ratio is N/A as of 2026-06-15, based on a stock price of $0.44 and TTM EPS of -$0.56. Data sourced from Financial Modeling Prep via AGNPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Algernon Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15